AU2008302276B2 - Method of conferring a protective immune response to norovirus - Google Patents

Method of conferring a protective immune response to norovirus Download PDF

Info

Publication number
AU2008302276B2
AU2008302276B2 AU2008302276A AU2008302276A AU2008302276B2 AU 2008302276 B2 AU2008302276 B2 AU 2008302276B2 AU 2008302276 A AU2008302276 A AU 2008302276A AU 2008302276 A AU2008302276 A AU 2008302276A AU 2008302276 B2 AU2008302276 B2 AU 2008302276B2
Authority
AU
Australia
Prior art keywords
vaccine
norovirus
vlps
virus
norwalk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008302276A
Other languages
English (en)
Other versions
AU2008302276A1 (en
Inventor
Thomas R. Foubert
Charles Richardson
William Tino
Thomas S. Vedvick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008302276(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2007303608A external-priority patent/AU2007303608B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Priority to AU2008302276A priority Critical patent/AU2008302276B2/en
Publication of AU2008302276A1 publication Critical patent/AU2008302276A1/en
Application granted granted Critical
Publication of AU2008302276B2 publication Critical patent/AU2008302276B2/en
Priority to AU2014200084A priority patent/AU2014200084B2/en
Assigned to TAKEDA VACCINES, INC. reassignment TAKEDA VACCINES, INC. Request to Amend Deed and Register Assignors: LIGOCYTE PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2008302276A 2006-09-29 2008-09-18 Method of conferring a protective immune response to norovirus Ceased AU2008302276B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2008302276A AU2008302276B2 (en) 2006-09-29 2008-09-18 Method of conferring a protective immune response to norovirus
AU2014200084A AU2014200084B2 (en) 2006-09-29 2014-01-08 Method of conferring a protective immune response to norovirus

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US60/847,912 2006-09-29
US97338907P 2007-09-18 2007-09-18
US60/973,389 2007-09-18
US60/973,392 2007-09-18
AU2007303608A AU2007303608B2 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations
US98682607P 2007-11-09 2007-11-09
US60/986,826 2007-11-09
PCT/US2008/076763 WO2009039229A2 (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus
AU2008302276A AU2008302276B2 (en) 2006-09-29 2008-09-18 Method of conferring a protective immune response to norovirus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2007303608A Division AU2007303608B2 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014200084A Division AU2014200084B2 (en) 2006-09-29 2014-01-08 Method of conferring a protective immune response to norovirus

Publications (2)

Publication Number Publication Date
AU2008302276A1 AU2008302276A1 (en) 2009-03-26
AU2008302276B2 true AU2008302276B2 (en) 2013-10-10

Family

ID=40468754

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008302276A Ceased AU2008302276B2 (en) 2006-09-29 2008-09-18 Method of conferring a protective immune response to norovirus

Country Status (9)

Country Link
US (5) US10130696B2 (cg-RX-API-DMAC10.html)
EP (1) EP2190471A4 (cg-RX-API-DMAC10.html)
JP (4) JP2010539192A (cg-RX-API-DMAC10.html)
KR (2) KR20150129042A (cg-RX-API-DMAC10.html)
CN (2) CN104740624B (cg-RX-API-DMAC10.html)
AU (1) AU2008302276B2 (cg-RX-API-DMAC10.html)
CA (1) CA2698397C (cg-RX-API-DMAC10.html)
SG (2) SG184733A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009039229A2 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
CA2804501C (en) * 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
WO2012122629A1 (en) 2011-03-11 2012-09-20 Mcmaster University A method of vaccination comprising a histone deacetylase inhibitor
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
CA2851917A1 (en) * 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
CN102559616B (zh) * 2012-02-24 2014-01-01 河南科技大学 一种含诺如病毒rna片段的假病毒颗粒及其制备方法
KR102283760B1 (ko) * 2012-06-21 2021-08-03 노쓰웨스턴유니버시티 펩티드 접합된 입자
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP2016533172A (ja) 2013-10-03 2016-10-27 タケダ ワクチン，インコーポレイテッド 細胞株からラブドウイルスを検出および除去する方法
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
CN106456546A (zh) * 2014-03-12 2017-02-22 葛兰素史密丝克莱恩生物有限公司 用于黏膜递送的脂质体组合物
AU2016317661B2 (en) 2015-08-28 2023-05-18 Ology Bioservices, Inc. Norovirus vaccine
JP6977206B2 (ja) * 2016-03-31 2021-12-08 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
JP2021534074A (ja) * 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115677838A (zh) * 2021-07-29 2023-02-03 成都康华生物制品股份有限公司 六价诺如病毒VLPs疫苗及其制备方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207526A1 (en) * 2005-11-22 2007-09-06 Doris Coit Norovirus and sapovirus antigens
WO2008042789A1 (en) * 2006-09-29 2008-04-10 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
AU683211B2 (en) 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ES2264126T3 (es) 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
WO1998044944A2 (en) 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
EP1105466B1 (en) 1998-08-14 2006-04-26 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
CA2354444A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
CA2375337C (en) 1999-06-22 2012-09-25 Naokazu Takeda Srsv detection kit
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2006074303A2 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
ES2424229T3 (es) 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
CA2608515A1 (en) 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production of multivalent virus like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CA2750321A1 (en) 2009-01-22 2010-07-29 Pharmathene, Inc. Stable vaccine compositions and methods of use
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
JP2013517773A (ja) 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
AU2016374497B2 (en) 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
JP2021534074A (ja) 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207526A1 (en) * 2005-11-22 2007-09-06 Doris Coit Norovirus and sapovirus antigens
WO2008042789A1 (en) * 2006-09-29 2008-04-10 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALL et al., Gasteroenterology July 1999, Vol.117, pages 40-48. *
TACKET, C. O., et al., Clinical immunology, 2003, Vol.,108, pages 241-247. *

Also Published As

Publication number Publication date
US20110182975A1 (en) 2011-07-28
US20240316175A1 (en) 2024-09-26
US20190381164A1 (en) 2019-12-19
JP6615063B2 (ja) 2019-12-04
JP2010539192A (ja) 2010-12-16
EP2190471A2 (en) 2010-06-02
JP2016196502A (ja) 2016-11-24
US20200345827A1 (en) 2020-11-05
CN104740624A (zh) 2015-07-01
CN104740624B (zh) 2018-04-24
HK1211473A1 (en) 2016-05-27
CN101918028B (zh) 2015-01-07
US11040097B2 (en) 2021-06-22
EP2190471A4 (en) 2012-05-09
SG184733A1 (en) 2012-10-30
US20220143169A1 (en) 2022-05-12
SG10201601660YA (en) 2016-04-28
WO2009039229A2 (en) 2009-03-26
US10130696B2 (en) 2018-11-20
CN101918028A (zh) 2010-12-15
AU2008302276A1 (en) 2009-03-26
US10688174B2 (en) 2020-06-23
KR20150129042A (ko) 2015-11-18
US11826415B2 (en) 2023-11-28
CA2698397C (en) 2018-03-27
WO2009039229A3 (en) 2009-09-03
KR20100083150A (ko) 2010-07-21
JP2019163328A (ja) 2019-09-26
JP6296885B2 (ja) 2018-03-20
JP2014141528A (ja) 2014-08-07
CA2698397A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
US20240316175A1 (en) Method of Conferring a Protective Immune Response to Norovirus
US10512682B2 (en) Norovirus vaccine formulations
US9821049B2 (en) Method of conferring a protective immune response to Norovirus
JP6613259B2 (ja) 非経口ノロウイルスワクチン製剤
AU2014200084B2 (en) Method of conferring a protective immune response to norovirus
AU2016250345A1 (en) Method of conferring a protective immune response to norovirus
HK1211473B (en) Vaccine of conferring a protective immune response to norovirus
HK1183794B (en) Norovirus vaccine formulations
HK1183794A (en) Norovirus vaccine formulations
HK1184057B (en) Norovirus vaccine formulations

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ VEDVICK, THOMAS S.; FOUBERT, THOMAS R.; RICHARDSON, CHARLES AND TINO, WILLIAM

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE DIVISIONAL DETAILS 2007303608 28 SEPTEMBER

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired